SCHEMBL3998019

SCHEMBL3998019

COC(=O)[C@H](CC[C@H](O[Si](C)(C)C(C)(C)C)c1ccc(F)cc1)[C@H](Nc1ccc(CN)cc1)c1ccc(OC)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.38
MEN1 O00255 5/20 0.38
MAPT P10636 3/20 0.38
MAPK1 P28482 2/20 0.38
POLB P06746 2/20 0.38
KDM4E B2RXH2 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 4/20 0.37
GAA P10253 1/20 0.37
KLK7 P49862 4/20 0.36
HTT P42858 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CRHBP P24387 1/20 0.36
CYP2C19 P33261 1/20 0.36
CRHR2 Q13324 1/20 0.36
FPR2 P25090 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3998015 1.00 KMT2A (0.38) KMT2AMEN1MAPTMAPK1POLB
SCHEMBL4005382 0.93 LMNA (0.39) KMT2AMEN1MAPTMAPK1POLB
SCHEMBL4005388 0.93 LMNA (0.39) KMT2AMEN1MAPTMAPK1POLB
SCHEMBL13764887 0.93 LMNA (0.39) KMT2AMEN1MAPTMAPK1POLB
SCHEMBL13764888 0.88 KMT2A (0.43) KMT2AMEN1MAPTMAPK1POLB
SCHEMBL4299269 0.87 KMT2A (0.35) KMT2AMEN1MAPTMAPK1POLB
SCHEMBL4299266 0.87 KMT2A (0.35) KMT2AMEN1MAPTMAPK1POLB
SCHEMBL4299268 0.87 KMT2A (0.35) KMT2AMEN1MAPTMAPK1POLB
SCHEMBL13764885 0.85 MEN1 (0.36) KMT2AMEN1MAPTMAPK1POLB
SCHEMBL3998788 0.85 MEN1 (0.36) KMT2AMEN1MAPTMAPK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7563888-B2 Process for the preparation of diphenyl azetidinone derivatives SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-21 US disclosed
US-20070149501-A1 PROCESS FOR THE PREPARATION OF DIPHENYL AZETIDINONE DERIVATIVES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-28 US disclosed
EP-1753717-A1 METHOD FOR PRODUCING DIPHENYL AZETIDINONE DERIVATIVES Sanofi-Aventis Deutschland GmbH (DE) 2007-02-21 EP disclosed
WO-2005113495-A1 METHOD FOR PRODUCING DIPHENYL AZETIDINONE DERIVATIVES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149501-A1 PROCESS FOR THE PREPARATION OF DIPHENYL AZETIDINONE DERIVATIVES CYP46A1, APOB, DHCR7 KMT2A 1869/4885MEN1 1200/4885MAPT 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.